Why the study?
C21, an angiotensin II type 2 receptor agonist, has shown neurovascular protection after stroke, but its direct anti-inflammatory effects on macrophages and brain innate immune cells needed investigation.
Does C21 reduce LPS-induced inflammation and ROS generation in murine microglia and macrophages?
Does C21 reduce LPS-induced inflammation and ROS generation in murine microglia and macrophages?
C21 demonstrates anti-inflammatory and neuroprotective effects in microglia and macrophages in vitro, suggesting potential therapeutic implications for stroke.
C21 attenuates macrophage inflammation in vitro; leaves open translation to clinical stroke neuroprotection.
BACKGROUND: (C21), an angiotensin II type 2 receptor agonist, has shown some neurovascular protection after stroke. This study aimed to investigate the direct anti-inflammatory effects of C21 on macrophages, as well as brain innate immune cells. METHODS: Murine microglial cell line (C8-B4) and RAW 264.7 macrophages were exposed to lipopolysaccharide (LPS) and co-treated with C21. Pro-inflammatory mediators were assessed via RT-qPCR and ELISA. Cellular reactive oxygen species (ROS) were evaluated via CellROXGreen staining, and nitrate production was assessed using Griess assay. RESULTS: C21 suppressed LPS-induced inflammation and ROS generation in both cells. In microglia, C21 blunted LPS-induced mRNA expression of IL-1β, IL-12b, COX-1, iNOS, and IL-6. A similar pattern was observed in macrophages, where C21 suppressed LPS-induced IL-1β, TNF-α, and CXCL1 expression. These anti-inflammatory effects in microglia and macrophages were associated with increased neuroprotective gene expression, including GDNF and BDNF, in a dose-dependent manner. CONCLUSIONS: Our findings suggest a protective effect of C21 against the inflammatory response, in both macrophages and microglia, via suppression of the release of pro-inflammatory cytokines/chemokines and the generation of ROS while stimulating the production of neurotrophic factors.
No takes yet. Share an insight, caveat, or question.
Alshammari et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: